Canadians are paying a fraction of what Americans shell out for generic Ozempic. The UK’s pricing watchdog has taken note, and rightly so. This is not merely a story about pharmaceutical greed. It is a parable about the intellectual and moral decadence of a nation that once led the world.
Consider the facts. A month’s supply of the drug costs $93 in Canada. In the United States, the price tag soars to $936. That is a tenfold difference for the exact same product, manufactured by the exact same company. The British National Institute for Health and Care Excellence, ever the stern headmaster, is now studying how Canada achieves this. One suspects they will find the answer embarrassingly simple: Canada says no to price gouging. The United States says yes.
This is where the historical parallels become irresistible. The American Republic, like the late Roman Empire, has allowed its institutions to be hollowed out by a combination of greed, political paralysis, and a populace that has forgotten the meaning of civic virtue. The Founding Fathers warned against factions. They did not anticipate a faction called Big Pharma that would hold the nation’s health hostage for quarterly earnings reports.
Let us not mince words. The American healthcare system is a monument to intellectual decadence. It is a Rube Goldberg machine designed to extract maximum profit from human suffering. And the British, ever the pragmatists, are taking notes. But will they have the fortitude to follow Canada’s lead? Or will they succumb to the same lobbying pressures that have turned American healthcare into a sick joke?
The answer lies in national identity. The United Kingdom still retains a vestige of the Victorian belief in public good. But that belief is eroding. Every time a British politician extols the virtues of “American-style innovation,” they are unwittingly endorsing a system that charges a thousand dollars for a drug that costs a tenth of that to produce. They are choosing the profit motive over the public purse.
Meanwhile, Canada quietly demonstrates that a nation can have both innovation and affordability. The secret is not socialism. It is simply having the courage to tell a corporation: no. We will not allow you to bleed our citizens dry. That is the essence of national sovereignty.
The Ozempic disparity is a microcosm of a larger crisis. It is the canary in the coal mine of American decline. And the British, peering over the Atlantic, should take heed. The fall of Rome was not accompanied by a single dramatic event. It was a thousand small failures of leadership and will. The price of Ozempic is one such failure.
So let the UK’s pricing watchdog take its notes. Let them study Canada. And let them act before the same decay reaches their own shores. Otherwise, they will find themselves writing the same column in a decade, about a drug that costs ten times what it should, and a nation that forgot what it meant to say no.
